Davalintide

DB14956InvestigationalProtein Based Therapies

Davalintide is under investigation in clinical trial NCT00785408 (Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects).

Mechanism: Pharmacologically active on Calcitonin gene-related peptide type 1 receptor
Curator reviewed
Code names: AC2307

Resolves to

Compound

UNII668U999F9TCAS863919-85-1

Targets

Q16602CALCRL

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Davalintide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account